Status:
COMPLETED
VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation
Lead Sponsor:
Aerogen Pharma Limited
Collaborating Sponsors:
Ohio State University
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to investigate whether inhaled epoprostenol given via a breath actuated delivery system will help improve oxygen levels and treatment outcomes in patients with COVID-19 wh...
Detailed Description
This study will evaluate the potential therapeutic benefit of VentaProst in treating patients with COVID-19 at risk for respiratory and/ or cardiac/circulatory failure. This is a double-blind, placebo...
Eligibility Criteria
Inclusion
- Confirmed COVID-19 positive by RT-PCR test
- Patients who require invasive mechanical ventilation.
- Consent or professional consent obtained
Exclusion
- Patients on ECMO support.
- Patients receiving another inhalation research medication or inhaled nitric oxide.
- Not expected to survive for 48 hours.
- Allergy to Epoprostenol and its diluent
Key Trial Info
Start Date :
September 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 29 2021
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT04452669
Start Date
September 15 2020
End Date
June 29 2021
Last Update
July 31 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ohio State University
Columbus, Ohio, United States, 43210